Application Evaluation and Literature Review of Hydroxyethyl Starch 130/0.4 Sodium Chloride Injection in Our Hospital

Abstract

CLC Number:

CUI Xiang-li, QIU Shuang, SI Tu-wei, ZHAO Rui, WANG Ying, ZHOU Hong, HUANG Qian, GAI Di, LIU Li-hong. Application Evaluation and Literature Review of Hydroxyethyl Starch 130/0.4 Sodium Chloride Injection in Our Hospital[J]. Chinese Journal of Pharmacovigilance, 2014, 11(6): 358-361.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2014/V11/I6/358

References

[1] Dellinger R P, Levy M M,Rhodes A, et al. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsisand Septic Shock, 2012[J]. Intensive Care Med, 2013, 39(2):165-228.
[2] Myburgh J A, Finfer S, Bellomo R, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care[J]. N Engl J Med,2012,367(20): 1901-1911.
[3] Perner A, Haase N, Guttormsen A B, et al. Hydroxyethyl starch 130/0.4 versus Ringer's acetate in severe sepsis[J]. N Engl J Med,2012,367(2):124-134.
[4] Rioux J P, Lessard M, De Bortoli B, et al. Pentastarch 10% (250 kDa/0.45) is an independent risk factor of acute kidney injury following cardiac surgery[J]. Critical care medicine, 2009,37(4):1293-1298.
[5] Lissauer M E, Chi A, Kramer M E, et al. Association of 6% Hetastarch resuscitation with adverse outcomes in critically ill trauma patients[J]. Am J Surgery,2011,202(1):53-58.
[6] Schabinski F,Oishi J,Tuche F,et al. Effects of a predominantly hydroxyethyl starch (HES)-based and a predominantly non HES-based fluid therapy on renal function in surgical ICU patients[J].Intensive Care Medicine,2009, 35(9):1539-1547.
[7] Navickis R J, Haynes G R, Wilkes M M.Effect of hydroxyethyl starch on bleeding after cardio -pulmonary bypass: a meta-analysis of randomized trials[J]. J ThoracCardiovascSurg, 2012,144(3):223-230.
[8] FDA.Public Workshop-Risks and Benefits of Hydroxyethyl Starch Solutions[EB/OL]. (2012-09-06) [2014-05-04].http://www.fda.gov/BiologicsBloodVaccines/NewsEvents/Workshops Meetings Conf-erences /ucm313370.html.
[9] 宫本凤, 毕可波, 刘新华,等. 低分子706代血浆致急性肾衰35 例分析[J].滨州医学院学报,1996, 16(4):362.
[10] 肖玲.706代血浆致急性肾功能衰竭10例临床分析[J].临床荟萃,2001,16(24):1123-1124.
[11] 李文杰,李慧. 羟乙基淀粉的不良反应[J].中国药业,2006,15（3）：76-77.
[12] EMA. PRAC confirms that hydroxyethyl-starch solutions（HES） should no longer be used in patients with sepsis or burn injuries or in critically ill patients[EB/OL]. (2013-10-11)[2014-05-04]http://www.ema.europaeu/docs/en_GB/document_library/Press_release /2013/10/WC500151964.pdf.
[13] SFDA.羟乙基淀粉40、20氯化钠注射液与肾功能损害.药品不良反应信息通报[EB/OL].(2005-04-18)[2014-05-04].http://www.sfda.gov.cn/WS01/CL0078 /11280.Html.

[1]	ZHAO Jie, GAO Minge, CHANG Hong, FAN Huixia. Pathogen Distribution, Drug Resistance and Drug Use in Neonates with Necrotizing Enterocolitis Complicated with Sepsis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 909-913.
[2]	QI Yujie, WANG Xin, ZHANG Jiahui, MA Enlong, GENG Xingchao. Research Progress in Integration Sites for Cellular and Gene Therapy Products [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 721-727.
[3]	LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan. Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785.
[4]	ZHU Huijuan, REN Jingtian. Safety Risks of Human Rabies Immunoglobulin [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 786-789.
[5]	LI Qiurong, FU Miaoqing, ZHOU Baishui, LI Cui, XIAO Xiaotong, YU Yuping, DENG Lu. Mining of Real-World ADR Signals Related to Cefradine for Injection in 268 Cases [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 790-793.
[6]	LI Can, LIU Lehuan, CHEN Xia, QU Jianbo. Pharmacy of Chinese Medicine Compound Preparations Based on Human Experiences [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 564-569.
[7]	YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao. A National Pharmacovigilance Management System in a New Era [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281.
[8]	LIU Ying, XIONG Shunyu, XIONG Huiyu, CAI Fei, XU Mengdan, WANG Qing, REN Wei, XU Yan. Methods for Assessment of MAH Compliance with GVP [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 282-285.
[9]	ZHU Lan, SHAO Bo, ZHU Yan, DAI Jie, ZHONG Shiqi. Current Progress and Considerations in Updating the Safety Information in Labels of Chinese Traditional Patent Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 188-192.
[10]	LI Wenlong, JIA Juanjuan, HUANG Haiwei, YAO Jing, ZHANG Chunqing, WANG Yan, ZHANG Hui. Developments and Prospects of Radiopharmaceuticals in China [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 37-42.
[11]	SONG Fuyu, CAO Yi. Establishment of Key Performance Indicators for Drug Inspection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(12): 1411-1414.
[12]	ZHAO Peipei, WEN Baoshu. Regulation of cellular and gene therapies at home and abroad [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1019-1024.
[13]	YANG Le, SHAN Lianlian, WANG Yali, YAN Shunhua, ZHOU Gang, CHEN Jia, WEI Feng. Quality standard for licorice of different sources [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1025-1028.
[14]	SUN Yixin, NIE Xiaolu, WANG Xiaoling, GUO Peng. Comparative research on active post-marketing drug safety surveillance systems worldwide based on real-world data [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 892-899.
[15]	WEI Fenfang, WU Wenyu, LI Limin, TANG Biyu, WU Jianru. Foreign methods for benefit-risk assessment of pharmaceutical products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 900-905.